{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:19:18Z","timestamp":1740460758024,"version":"3.37.3"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1183\/13993003.00523-2024","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T08:25:38Z","timestamp":1718871938000},"page":"2400523","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The evidence base for ICS\/formoterol maintenance and reliever therapy in severe asthma"],"prefix":"10.1183","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-406X","authenticated-orcid":false,"given":"Richard","family":"Beasley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7620-3125","authenticated-orcid":false,"given":"Jonathan","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-9107","authenticated-orcid":false,"given":"Mark","family":"Weatherall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"2024102017295533000_63.6.2400523.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01844-2023"},{"key":"2024102017295533000_63.6.2400523.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023"},{"key":"2024102017295533000_63.6.2400523.3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200308"},{"key":"2024102017295533000_63.6.2400523.4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3109\/02770903.2015.1056350","article-title":"Fluticasone furoate (FF)\/vilanterol (100\/25 mcg or 200\/25 mcg) or FF (100 mcg) in persistent asthma","volume":"52","author":"Bernstein","year":"2015","journal-title":"J Asthma"},{"key":"2024102017295533000_63.6.2400523.5","doi-asserted-by":"crossref","first-page":"106021","DOI":"10.1016\/j.rmed.2020.106021","article-title":"Fixed-dose combination of indacaterol\/ glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomized, phase IIIb, non-inferiority study (ARGON)","volume":"170","author":"Gessner","year":"2020","journal-title":"Respir Med"},{"key":"2024102017295533000_63.6.2400523.6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2213-2600(20)30178-8","article-title":"Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study","volume":"8","author":"van Zyl-Smit","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102017295533000_63.6.2400523.7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","article-title":"Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study","volume":"10","author":"Kerstjens","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102017295533000_63.6.2400523.8","first-page":"69","article-title":"Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial","volume":"9","author":"Lee","year":"2021","journal-title":"Lancet"},{"key":"2024102017295533000_63.6.2400523.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.07.014"},{"key":"2024102017295533000_63.6.2400523.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00028305"},{"key":"2024102017295533000_63.6.2400523.11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2213-2600(13)70007-9","article-title":"Efficacy and safety of maintenance and reliever combination budesonide\u2013formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial","volume":"1","author":"Patel","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102017295533000_63.6.2400523.12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2500\/aap.2014.35.3729","article-title":"Budesonide\/formoterol maintenance and reliever therapy in moderate-to-severe asthma: effects on eosinophilic airway inflammation","volume":"35","author":"Takeyama","year":"2014","journal-title":"Allergy Asthma Proc"},{"key":"2024102017295533000_63.6.2400523.13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"2024102017295533000_63.6.2400523.14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaip.2023.01.002","article-title":"The ICS\/formoterol reliever therapy regimen in asthma: a review","volume":"11","author":"Beasley","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102017295533000_63.6.2400523.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.2769"},{"key":"2024102017295533000_63.6.2400523.16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12890-019-1014-4","article-title":"Dose\u2013response relationship of ICS\/fast-onset LABA as reliever therapy in asthma","volume":"19","author":"Beasley","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2024102017295533000_63.6.2400523.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69284-2"},{"key":"2024102017295533000_63.6.2400523.18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00625-2020"},{"key":"2024102017295533000_63.6.2400523.19","first-page":"CD003534","article-title":"Fluticasone at different doses for chronic asthma in adults and children","volume":"4","author":"Adams","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102017295533000_63.6.2400523.20","doi-asserted-by":"crossref","first-page":"1901147","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur Respir J"},{"key":"2024102017295533000_63.6.2400523.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.040982020"},{"key":"2024102017295533000_63.6.2400523.22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archinte.159.9.941","article-title":"Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis","volume":"139","author":"Lipworth","year":"1999","journal-title":"Arch Intern Med"},{"key":"2024102017295533000_63.6.2400523.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1868CI"},{"key":"2024102017295533000_63.6.2400523.24","unstructured":"Global Initiative for Asthma . Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) Update 2023. www.ginasthma.org\/"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00523-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:21:05Z","timestamp":1740381665000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00523-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,20]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1183\/13993003.00523-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00523-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"type":"print","value":"0903-1936"},{"type":"electronic","value":"1399-3003"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}